Vistagen Therapeutics, Inc. (VTGN)
2025-06-30 | 2024-12-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 244 | 234 | 183 | 84 |
| Research and development | 11,678 | 11,305 | 10,215 | 7,648 |
| General and administrative | 4,370 | 4,049 | 4,195 | 4,567 |
| Total operating expenses | 16,048 | 15,354 | 14,410 | 12,215 |
| Loss from operations | -15,804 | -15,120 | -14,227 | -12,131 |
| Interest income, net | 711 | 1,031 | 1,273 | 1,398 |
| Other expense | -2 | - | - | - |
| Loss before income taxes | -15,095 | -14,089 | -12,954 | -10,733 |
| Income taxes | - | - | 7 | - |
| Net loss | -15,095 | -14,089 | -12,961 | -10,733 |
| Unrealized gain (loss) on marketable securities | -4 | -11 | 20 | 2 |
| Comprehensive loss | -15,099 | -14,100 | -12,941 | -10,731 |
| Basic, net loss per common share (in dollars per share) | -0.47 | -0.46 | -0.42 | -0.35 |
| Diluted, net loss per common share (in dollars per share) | -0.47 | -0.46 | -0.42 | -0.35 |
| Weighted average common shares outstanding, basic (in shares) | 31,930,665 | 30,711,872 | 30,632,347 | 30,603,435 |
| Weighted average common shares outstanding, diluted (in shares) | 31,930,665 | 30,711,872 | 30,632,347 | 30,603,435 |